In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
AstraZeneca shares, meanwhile, were less-than-moved by the news.
Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.
The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.
Animal health and oncology deal activity is heating up in 2017.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.